SANBIO CO. LTD. Aktie

SanBio reported increased net losses of -3,842 million JPY for fiscal 2026, driven by higher sales and R&D expenses ahead of commercialization. A capital increase raised about 16.2 billion JPY, cash and cash equivalents rose to 15,083 million JPY and net assets to 13,604 million JPY. Inclusion of AKUUGO in the national reimbursement list (NHI) is expected in May 2026; initial deliveries are planned for H2 2026. SanBio anticipates substantially higher expenses and another loss in 2027, but is not publishing revenue forecasts until reimbursement details are confirmed. » More on de.investing.com

SanBio reported Q2 2025 earnings per share of -6.42, missing estimates, after which the stock fell 1.57% in after-hours trading. Despite the earnings decline, the company secured credit lines of 3 billion yen and received approval for its therapeutic AKUUGO to treat chronic traumatic brain injuries. SanBio plans to expand indications to stroke and other neurological disorders, as well as to expand into the U.S. and strengthen its presence in Japan, while raising its operating cost forecasts. » More on de.investing.com

SanBio reports sharply higher R&D expenses for Q2 FY2026 and a widened net loss of 1.997 million yen. The company has agreed with the FDA on the design of a phase‑3 study for traumatic brain injury and expects approval of a partial amendment for AKUUGO in the second half of the fiscal year. SanBio secures liquidity through credit lines of 3 billion yen, is building production capacity, and aims to launch in Japan in early FY2027 while preparing for US studies. » More on de.investing.com